BIMZELX® (bimekizumab-bkzx) is the first and only IL-17A and IL-17F inhibitor approved for the treatment of adults with moderate to severe plaque psoriasis Approval is supported by three Phase 3 trials where bimekizumab consistently delive...
/PRNewswire/ -- Regulated Information – Inside Information – UCB, a global biopharmaceutical company, announced today that the U.S. Food and Drug...
Head of Patient Impact and Chief Commercial Officer, UCB. "In psoriatic arthritis and across the spectrum of axSpA, clinical study results and real-world experience outside the U.S. have highligh...
Movement from concept to commercial product is uncertain; preclinical results do not guarantee safety and efficacy of product candidates in humans. So far, the complexity of the human body cannot be reproduced in computer models, cel...
Study underscores UCB's belief in BIMZELX with top-line results expected in 2026 ATLANTA,Sept. 30, 2024/PRNewswire/ -- UCB, a global biopharmaceutical company, today announced the start of BE BOLD, a head-to-head Phase 3b study, comparing BIMZELX®(bimekizumab-bkzx), an interleukin ...
Movement from concept to commercial product is uncertain; preclinical results do not guarantee safety and efficacy of product candidates in humans. So far, the complexity of the human body cannot be reproduced in computer mode...